M
Marker Therapeutics, Inc. (MRKR)
NCM – Real Time Price. Currency in USD
1.30
-0.05 (-3.70%)
At close: Mar 27, 2026, 4:00 PM EDT
1.30
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
1.30
-0.05 (-3.70%)
At close: Mar 27, 2026, 4:00 PM EDT
1.30
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. Maria-Bernadette Madel Ph.D. | Director of Corporate Operations & External Communications |
| Dr. Robert Z. Florkiewicz Sr., Ph.D. | Senior Director of Molecular Biology & Virology |
| Mr. Edmund Cheung | Vice President of Human Resources |
| Ms. Elizabeth Donnelly | Director of Administration |
| Ms. Mary Newman Ph.D. | Head of Regulatory Affairs |
| Patricia Allison | Head of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | DEF 14A | tm261499-3_def14a.htm |
| 2026-03-19 | 8-K | tm268941d1_8k.htm |
| 2026-03-18 | 10-K | mrkr-20251231x10k.htm |
| 2026-03-10 | PRE 14A | tm261499-1_pre14a.htm |
| 2025-11-14 | 8-K | tm2530894d1_8k.htm |
| 2025-11-13 | 10-Q | mrkr-20250930x10q.htm |
| 2025-11-05 | 8-K | tm2530129d1_8k.htm |
| 2025-10-06 | 8-K | tm2527906d1_8k.htm |
| 2025-08-26 | 8-K | tm2524197d1_8k.htm |
| 2025-08-14 | 10-Q | mrkr-20250630x10q.htm |